Table 2 Univariable and multivariable analyses of factors associated with OS—combined datasets.
Characteristic | Univariable | Multivariable | ||
|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
OS—baseline indices (n = 348) | ||||
Age | 0.99 (0.98–1.00) | 0.24 | 0.99 (0.98–1.00) | 0.15 |
Male sex | 1.24 (0.91–1.68) | 0.18 | 1.34 (0.98–1.85) | 0.07 |
Baseline BMI | 1.01 (0.98–1.03) | 0.63 | — | — |
Baseline BMI > 25 | 1.13 (0.81–1.60) | 0.46 | 1.08 (0.77–1.53) | 0.65 |
irAE prior to cycle 5 | 0.39 (0.28–0.54) | 6.4 × 10−9 | 0.32 (0.22–0.49) | 6.7 × 10−8 |
Single agent anti-PD1 | 1.48 (1.06–2.06) | 0.02 | 0.76 (0.49–1.19) | 0.23 |
Prior systemic therapy | 1.36 (0.91–2.03) | 0.14 | 1.31 (0.86–1.99) | 0.21 |
OS—including biochemical and haematological indices (n = 276) | ||||
Age | — | — | 1.01 (0.98–1.01) | 0.53 |
Male sex | — | — | 1.48 (1.02–2.14) | 0.04 |
Baseline BMI > 25 | — | — | 0.88 (0.58–1.34) | 0.56 |
irAE prior to cycle 5 | — | — | 0.31 (0.20–0.49) | 2.5 × 10−7 |
Anti-PD1 treatment | — | — | 1.05 (0.62–1.77) | 0.86 |
Prior systemic therapy | — | — | 1.30 (0.8–2.1) | 0.28 |
Baseline neutrophil | 1.19 (1.13–1.26) | 4.9 × 10−10 | 1.16 (1.08–1.24) | 2.8 × 10−5 |
Baseline lymphocyte | 1.11 (0.66–1.23) | 0.53 | 0.97 (0.73–1.29) | 0.84 |
Low albumin (per centre) | 4.7 (2.87–7.70) | 8.1 × 10−10 | 2.77 (1.55–4.95) | 5.8 × 10−4 |
